Central Trust CO Abb Vie Inc. Transaction History

Central Trust CO

$4.19 Billion
Q3 2024

A detailed history of Central Trust CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Central Trust CO holds 229,325 shares of ABBV stock, worth $39.1 Million. This represents 1.08% of its overall portfolio holdings.

Number of Shares

229,325

Previous 234,034 2.01%

Holding current value

$39.1 Million

Previous $40.1 Million 12.82%

% of portfolio

1.08%

Previous 1.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	SELL	$163.84 - $199.33 $771,522 - $938,644	-4,709 Reduced 2.01%	229,325 $45.3 Million
Q2 2024 Aug 05, 2024	SELL	$154.79 - $180.76 $892,519 - $1.04 Million	-5,766 Reduced 2.4%	234,034 $40.1 Million
Q1 2024 Apr 24, 2024	SELL	$159.82 - $182.1 $1.32 Million - $1.5 Million	-8,229 Reduced 3.32%	239,800 $43.7 Million
Q4 2023 Jan 24, 2024	SELL	$137.6 - $154.97 $272,172 - $306,530	-1,978 Reduced 0.79%	248,029 $38.4 Million
Q3 2023 Oct 26, 2023	SELL	$133.59 - $154.65 $436,972 - $505,860	-3,271 Reduced 1.29%	250,007 $37.3 Million
Q2 2023 Jul 26, 2023	SELL	$132.51 - $164.9 $642,540 - $799,600	-4,849 Reduced 1.88%	253,278 $34.1 Million
Q1 2023 Apr 19, 2023	SELL	$144.61 - $166.54 $299,487 - $344,904	-2,071 Reduced 0.8%	258,127 $41.1 Million
Q4 2022 Jan 26, 2023	SELL	$138.31 - $165.87 $1.12 Million - $1.35 Million	-8,126 Reduced 3.03%	260,198 $0
Q3 2022 Nov 17, 2022	BUY	$134.21 - $153.93 $1.6 Million - $1.83 Million	11,896 Added 4.64%	268,324 $36 Million
Q2 2022 Aug 09, 2022	SELL	$137.62 - $174.96 $807,829 - $1.03 Million	-5,870 Reduced 2.24%	256,428 $39.3 Million
Q1 2022 May 03, 2022	SELL	$131.98 - $163.75 $246,010 - $305,230	-1,864 Reduced 0.71%	262,298 $42.5 Million
Q4 2021 Feb 08, 2022	BUY	$107.43 - $135.93 $85,299 - $107,928	794 Added 0.3%	264,162 $35.8 Million
Q3 2021 Oct 19, 2021	BUY	$106.4 - $120.78 $534,021 - $606,194	5,019 Added 1.94%	263,368 $28.4 Million
Q2 2021 Jul 23, 2021	BUY	$105.21 - $117.21 $419,682 - $467,550	3,989 Added 1.57%	258,349 $29.1 Million
Q1 2021 Apr 23, 2021	BUY	$102.3 - $112.62 $366,029 - $402,954	3,578 Added 1.43%	254,360 $27.5 Million
Q4 2020 Jan 29, 2021	BUY	$80.49 - $108.67 $394,561 - $532,700	4,902 Added 1.99%	250,782 $26.9 Million
Q3 2020 Oct 22, 2020	BUY	$85.91 - $100.83 $563,827 - $661,747	6,563 Added 2.74%	245,880 $21.5 Million
Q2 2020 Jul 14, 2020	BUY	$73.37 - $98.18 $1.01 Million - $1.35 Million	13,795 Added 6.12%	239,317 $23.5 Million
Q1 2020 Apr 17, 2020	BUY	$64.5 - $97.79 $535,995 - $812,634	8,310 Added 3.83%	225,522 $17.2 Million
Q4 2019 Jan 21, 2020	BUY	$72.13 - $90.25 $1.43 Million - $1.78 Million	19,769 Added 10.01%	217,212 $19.2 Million
Q3 2019 Oct 28, 2019	BUY	$62.98 - $75.72 $200,150 - $240,638	3,178 Added 1.64%	197,443 $15 Million
Q2 2019 Jul 12, 2019	BUY	$65.7 - $83.98 $171,345 - $219,019	2,608 Added 1.36%	194,265 $0
Q1 2019 Apr 26, 2019	SELL	$77.14 - $90.79 $1.58 Million - $1.86 Million	-20,513 Reduced 9.67%	191,657 $0
Q4 2018 Jan 08, 2019	SELL	$77.85 - $96.01 $497,227 - $613,215	-6,387 Reduced 2.92%	212,170 $19.6 Million
Q3 2018 Oct 04, 2018	SELL	$88.91 - $98.84 $3.26 Million - $3.63 Million	-36,707 Reduced 14.38%	218,557 $0
Q2 2018 Jul 09, 2018	BUY	$89.78 - $106.23 $28,370 - $33,568	316 Added 0.12%	255,264 $0
Q1 2018 Apr 04, 2018	SELL	$92.01 - $123.21 $201,409 - $269,706	-2,189 Reduced 0.85%	254,948 $0
Q4 2017 Jan 23, 2018	SELL	$89.56 - $98.21 $521,328 - $571,680	-5,821 Reduced 2.21%	257,137 $0
Q3 2017 Oct 17, 2017	BUY	$69.85 - $89.22 $18.4 Million - $23.5 Million	262,958	262,958 $0

Others Institutions Holding ABBV

# of Institutions

3,869

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $302B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Central Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Central Trust CO with notifications on news.

Account